Document is current
Any future updates will be listed below
-
Authors
Viswanathan, Thiruselvam https://orcid.org/0000-0001-9817-6730
Arya, Shailee https://orcid.org/0000-0002-7689-7411
Chan, Siu-Hong https://orcid.org/0000-0002-9554-7273
Qi, Shan https://orcid.org/0000-0003-0175-6267
Dai, Nan https://orcid.org/0000-0003-3268-1835
Misra, Anurag
Park, Jun-Gyu https://orcid.org/0000-0001-7163-3591
Oladunni, Fatai https://orcid.org/0000-0001-5050-0183
Kovalskyy, Dmytro
Hromas, Robert A.
Martinez-Sobrido, Luis https://orcid.org/0000-0001-7084-0804
Gupta, Yogesh K. https://orcid.org/0000-0001-6372-5007
-
Funding
Funding for this research was provided by:
Max and Minnie Tomerlin Voelcker Fund
San Antonio Area Foundation
University of Texas Health San Antonio
- License Information
-
More Information
Article History
Received: 12 June 2020
Accepted: 4 July 2020
First Online: 24 July 2020
Competing interests
: Y.K.G is founder of Atomic Therapeutics. R.A.H. owns equity in Dialectic Therapeutics and Abfero. S-H.C. and N.D. are employees of New England Biolabs, a manufacturer and vendor of molecular biology reagents, including vaccinia RNA capping enzyme and cap 2’O methyltransferase. None of these affiliations affect the authors’ impartiality, adherence to journal standards and policies, or availability of data.
